RDDT

The shares are fully vested and will be settled in shares of the Issuer's Class A Common Stock either (i) on a date selected by the Reporting Person pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Program (the "Program"), or (ii) as otherwise provided by the Program.

The shares are fully vested and will be settled in shares of the Issuer's Class A Common Stock either (i) on a date selected by the Reporting Person pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Program (the "Program"), or (ii) as otherwise provided by the Program.

The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 3, 2026.

The sales were executed in multiple trades at prices ranging from $170.27 to $171.19. The price reported reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price within the ranges set forth in footnotes 2 to 6 to this Form 4.

The sales were executed in multiple trades at prices ranging from $171.29 to $172.27.

This transaction reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 19, 2025.

The sales were executed in multiple trades at prices ranging from $174.38 to $174.83.

The option vests over five years on each quarterly anniversary of December 25, 2023, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.

The sales were executed in multiple trades at prices ranging from $173.36 to $174.33.

The sales were executed in multiple trades at prices ranging from $172.33 to $173.31.

The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025.

The sales were executed in multiple trades at prices ranging from $177.74 to $178.71.

The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025.

The sales were executed in multiple trades at prices ranging from $176.73 to $177.72.

The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025.

The sales were executed in multiple trades at prices ranging from $178.74 to $179.61.

The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025.

The sales were executed in multiple trades at prices ranging from $181.92 to $181.95.

The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025.

The sales were executed in multiple trades at prices ranging from $179.99 to $180.05.

The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025.

The stock option is fully vested and currently exercisable.

The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025.

The sales were executed in multiple trades at prices ranging from $175.73 to $176.72.

The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025.

The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025.

The sales were executed in multiple trades at prices ranging from $174.73 to $175.71. The price reported reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price within the ranges set forth in this footnote 2 to 8.

The sales were executed in multiple trades at prices ranging from $171.22 to $171.52.

This transaction reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 19, 2025.

The sales were executed in multiple trades at prices ranging from $169.00 to $169.95. The price reported reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price within the ranges set forth in footnotes 2 to 13 to this Form 4.

The option vests over five years on each quarterly anniversary of December 25, 2023, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.

The sales were executed in multiple trades at prices ranging from $181.41 to $181.98.

The sales were executed in multiple trades at prices ranging from $174.14 to $175.00.

The sales were executed in multiple trades at prices ranging from $170.00 to $170.98.

The sales were executed in multiple trades at prices ranging from $180.30 to $181.28.

The sales were executed in multiple trades at prices ranging from $177.21 to $178.18.

The sales were executed in multiple trades at prices ranging from $172.97 to $173.93.

The sales were executed in multiple trades at prices ranging from $179.21 to $180.16.

The sales were executed in multiple trades at prices ranging from $176.18 to $177.17.

The sales were executed in multiple trades at prices ranging from $175.17 to $175.94.

The sales were executed in multiple trades at prices ranging from $178.21 to $179.19.

The shares represent restricted stock units, which will vest in full on the earlier of (i) the first anniversary of the grant date and (ii) immediately before the Issuer's annual meeting of stockholders to be held in 2027; subject to the Reporting Person's continued service through such vesting date.

The shares represent restricted stock units, which will vest in full on the earlier of (i) the first anniversary of the grant date and (ii) immediately before the Issuer's annual meeting of stockholders to be held in 2027; subject to the Reporting Person's continued service through such vesting date.

The shares represent restricted stock units ("RSUs"), which will vest in full on the earlier of (i) the first anniversary of the grant date and (ii) immediately before the Issuer's annual meeting of stockholders to be held in 2027; subject to the Reporting Person's continued service through such vesting date. The RSUs will be settled in accordance with the Reporting Person's deferral election under the Issuer's Amended and Restated Non-Employee Director Compensation Program or, if earlier, upon termination of the Reporting Person's service as a director.

The shares represent restricted stock units, which will vest in full on the earlier of (i) the first anniversary of the grant date and (ii) immediately before the Issuer's annual meeting of stockholders to be held in 2027; subject to the Reporting Person's continued service through such vesting date.

The shares represent restricted stock units ("RSUs"), which will vest in full on the earlier of (i) the first anniversary of the grant date and (ii) immediately before the Issuer's annual meeting of stockholders to be held in 2027; subject to the Reporting Person's continued service through such vesting date. The RSUs will be settled in accordance with the Reporting Person's deferral election under the Issuer's Amended and Restated Non-Employee Director Compensation Program or, if earlier, upon termination of the Reporting Person's service as a director.

The shares represent restricted stock units, which will vest in full on the earlier of (i) the first anniversary of the grant date and (ii) immediately before the Issuer's annual meeting of stockholders to be held in 2027; subject to the Reporting Person's continued service through such vesting date.

The shares represent restricted stock units, which will vest in full on the earlier of (i) the first anniversary of the grant date and (ii) immediately before the Issuer's annual meeting of stockholders to be held in 2027; subject to the Reporting Person's continued service through such vesting date.

This transaction reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 19, 2025.

The sales were executed in multiple trades at prices ranging from $175.84 to $176.49.

This transaction reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 19, 2025.

The sales were executed in multiple trades at prices ranging from $168.28 to $168.89.

This transaction reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 19, 2025.

The sales were executed in multiple trades at prices ranging from $170.62 to $171.23.

This transaction reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 19, 2025.

The sales were executed in multiple trades at prices ranging from $174.84 to $175.82.

This transaction reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 19, 2025.

The sales were executed in multiple trades at prices ranging from $172.76 to $173.75.

This transaction reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 19, 2025.

The sales were executed in multiple trades at prices ranging from $167.05 to $168.02. The price reported reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price within the ranges set forth in footnotes 2 to 9 to this Form 4.